Abstract
Isoniazid is effective in preventing tuberculous complications, thus minimizing the danger of primary tuberculosis. Isoniazid is a remarkably effective agent for the treatment of all clinical forms of tuberculosis in children. Since effective therapy is now available, every effort should be made to seek out the infected children by routine tuberculin testing so that they may receive the benefit of INH therapy in the early stage of the infection. Special attention should be given to children under 36 months of age because of the high mortality and morbidity rates of tuberculosis at this age period. In countries where tuberculosis incidence is low and where BCG vaccine is not in general use, routine tuberculin testing of young children serves the dual-purpose of early treatment of primary tuberculosis in children and the detection of unrecognized tuberculosis in adults.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
